Adaptin Bio (APTN) Profit After Tax (2023 - 2026)

Adaptin Bio has disclosed Profit After Tax across 4 years of filings, most recently posting -$1.1 million for Q1 2026.

• Quarterly Profit After Tax fell 90.04% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.7 million (down 68.64% YoY) and the FY2025 annual result came in at -$5.2 million, down 65.49% from the prior year.
• Profit After Tax rose to -$1.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$4250.0 in Q1 2023 and bottomed at -$1.7 million in Q3 2025.
• The 4-year median for Profit After Tax is -$818738.0 (2024), against an average of -$732447.3.
• Year-over-year, Profit After Tax tumbled 19164.42% in 2024 and plunged 51.29% in 2025.
• Adaptin Bio's Profit After Tax stood at -$34155.0 in 2023, then sank by 2408.67% to -$856836.0 in 2024, then tumbled by 59.66% to -$1.4 million in 2025, then climbed by 16.22% to -$1.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$1.1 million, -$1.4 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.